Week-long event aims to help commercialize innovations to reach patients in need.
Taking place from Monday, January 25 to Friday, January 29, 2021, MassBio’s Partnering Week is a week-long event that connects early-stage companies developing breakthrough technologies with leading biopharmaceutical, medical device, diagnostic, and digital health organizations in complementary focus areas for partnering opportunities. Each day is dedicated to one sponsor who will begin with an overview presentation on the organization’s research and development strategy, partnering approaches, therapeutic areas, and 2021 outlook. The sponsor will then host one-on-one meetings with selected startups. The overview sessions are open to the public.
The sponsors of the event and dates of their respective overview sessions are: Biogen (January 25th), Johnson & Johnson Innovation (January 26th), EMD Serono (January 27th), and BeiGene (January 28th).
For more information, click here.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.